Clinical Trial Update: Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy, safety, and pharmacokinetics of bilastine 10 mg or 20 mg given once or twice daily versus placebo for symptomatic treatme…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis
• Seasonal Allergic Rhinitis

Drugs mentioned

• Bilastine (bilastine)

Snippet

Sponsor: Faes Farma, S.A. | Conditions: Seasonal Allergic Rhinitis, Hay Fever | Phase 2 | Status: COMPLETED